<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE html
  PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns:act="http://www.gov.bc.ca/2013/legislation/act" xmlns:reg="http://www.gov.bc.ca/2013/legislation/regulation" xmlns:bcl="http://www.gov.bc.ca/2013/bclegislation" xmlns:in="http://www.qp.gov.bc.ca/2013/inline" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:oasis="http://docs.oasis-open.org/ns/oasis-exchange/table" xmlns:ms="urn:schemas-microsoft-com:xslt" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><title>Point in Time - Opioid Damages and Health Care Costs Recovery Act</title><link href="/standards/pit.css" rel="stylesheet" type="text/css" /><link href="/standards/Acts.css" rel="stylesheet" type="text/css" /><script src="https://code.jquery.com/jquery-1.7.1.min.js" type="text/javascript"></script><script src="/standards/hitNav.js" type="text/javascript"></script><script type="text/javascript">function launchNewWindow(url)
{
	window.open(url,'','toolbar=1,scrollbars=1,location=0,statusbar=1,menubar=1,resizable=1,');
}
</script><style type="text/css">
					#toolBar {
					position:fixed;
					top:5px;
					left:0;
					width: 100%;
					height: 20px;
					padding: 5px 10px;
					border-bottom: 3px solid #333; /* some styling */
					}
				</style><style type="text/css" media="print">
					#contentsscroll{
					height: auto;
					overflow-y: auto;
					}
					#toolBar{
					display: none; 
					}
				</style><style type="text/css" media="screen">
					#contentsscroll{
					height: 90%;
					width: 96%;
					position: absolute;
					margin-left: 20px;
					margin-top: 40px;
					overflow: auto;
					}
				</style></head><body bgcolor="#FFFFFF" text="#000000"><div xmlns="" xmlns:xs="http://www.w3.org/2001/XMLSchema" id="toolBar"><a id="searchHit" href="#">Search Results</a> | <a id="clearSearch" href="#">Clear Search</a> | <a id="prevHit" href="#">Previous (in doc)</a> | <a id="nextHit" href="#">Next (in doc)</a> | <a id="pdocHit" href="#">Prev Doc</a> | <a id="ndocHit" href="#">Next Doc</a></div><div id="contentsscroll"><div id="header"><table border="0" cellpadding="4" cellspacing="0" width="100%"><tr><td align="left" class="sizesmall" valign="bottom">Copyright © King's						Printer,<br /> Victoria, British Columbia, Canada</td><td align="right" class="sizemedium"><a href="/standards/Licence.html" target="_blank"><strong>Licence</strong></a><br /><a href="/standards/Disclaimer.html" target="_blank"><strong>Disclaimer</strong></a></td></tr></table></div><div id="title"><h2>“Point in Time” Act Content</h2><h3>OPIOID DAMAGES AND HEALTH CARE COSTS RECOVERY ACT</h3><h4>[SBC 2018] CHAPTER 35</h4></div><div id="contentpit"><table border="0" cellpadding="3" cellspacing="0"><tbody><tr><td class="smalltext" colspan="2"> NOTE: <em>Links below go to act  content as								it was prior to the changes made on the effective date. (PIT covers
								changes made from September 6, 2000 to
								"current to" date of the act.)
							</em></td></tr><tr><th>SECTION</th><th class="sec">EFFECTIVE DATE</th></tr><tr><td align="center" valign="top">1</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit1">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit2">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit3">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit4">November 3, 2022</a></td></tr><tr><td align="center" valign="top">2</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit5">November 3, 2022</a></td></tr><tr><td align="center" valign="top">2.1</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit6">November 3, 2022</a></td></tr><tr><td align="center" valign="top">3</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit7">November 3, 2022</a></td></tr><tr><td align="center" valign="top">4</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit8">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit9">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit10">November 3, 2022</a></td></tr><tr><td align="center" valign="top">5</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit11">November 3, 2022</a></td></tr><tr><td align="center" valign="top">6</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit12">November 3, 2022</a></td></tr><tr><td align="center" valign="top">7</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit13">November 3, 2022</a></td></tr><tr><td align="center" valign="top"> </td><td align="center" class="sec" valign="top" width="60%"><a href="#pit14">November 3, 2022</a></td></tr><tr><td align="center" valign="top">7.1</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit15">November 3, 2022</a></td></tr><tr><td align="center" valign="top">10</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit16">November 3, 2022</a></td></tr><tr><td align="center" valign="top">Schedule</td><td align="center" class="sec" valign="top" width="60%"><a href="#pit17">November 3, 2022</a></td></tr></tbody></table></div><div id="mainpit"><div class="pitfirst"><p class="reference"><a name="pit1"> 			</a>Section 1 (1) definitions of "active ingredient" and "consultant" were added by 2022-34-1(a), effective November 3, 2022 (Royal Assent).</p></div><div class="pit"><p class="reference"><a name="pit2"> 
			</a>Section 1 (1) definitions of "cost of health care benefits", "health care benefits", "manufacturer", "opioid product" and "opioid-related wrong" BEFORE amended by 2022-34-1(b) to (f), effective November 3, 2022 (Royal Assent).</p><p id="d1e44" class="def"><span id="cost+of+health+care+benefits" class="normal-bold-style">"cost of health care benefits"</span> means the sum of</p><p class="para"><a name="d1e51"></a><span class="num"><span class="holder">(a)</span></span> the present value of the total expenditure by the government for health care benefits provided for insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness, and</p><p class="para"><a name="d1e60"></a><span class="num"><span class="holder">(b)</span></span> the present value of the estimated total expenditure by the government for health care benefits that could reasonably be expected to be provided for those insured persons as a result of opioid-related disease, injury or illness or the risk of opioid-related disease, injury or illness;</p><p id="d1e78" class="def"><span id="health+care+benefits" class="normal-bold-style">"health care benefits"</span> means</p><p class="para"><a name="d1e85"></a><span class="num"><span class="holder">(a)</span></span> benefits as defined under the <em>Hospital Insurance Act</em>,</p><p class="para"><a name="d1e98"></a><span class="num"><span class="holder">(b)</span></span> benefits as defined under the <em>Laboratory Services Act</em>,</p><p class="para"><a name="d1e111"></a><span class="num"><span class="holder">(c)</span></span> benefits as defined under the <em>Medicare Protection Act</em>,</p><p class="para"><a name="d1e124"></a><span class="num"><span class="holder">(d)</span></span> benefits as defined under the <em>Pharmaceutical Services Act</em>,</p><p class="para"><a name="d1e138"></a><span class="num"><span class="holder">(e)</span></span> payments made by the government under the <em>Continuing Care Act</em>, and</p><p class="para"><a name="d1e151"></a><span class="num"><span class="holder">(f)</span></span> other expenditures by the government, made directly or through one or more agents or other intermediate bodies, for programs, services, benefits or similar matters associated with disease, injury or illness;</p><p id="d1e222" class="def"><span id="manufacturer" class="normal-bold-style">"manufacturer"</span> means a person who manufactures or has manufactured an opioid product and a person who, in the past or currently,</p><p class="para"><a name="d1e229"></a><span class="num"><span class="holder">(a)</span></span> causes, directly or indirectly, through arrangements with contractors, subcontractors, licensees, franchisees or others, the manufacture of an opioid product,</p><p class="para"><a name="d1e238"></a><span class="num"><span class="holder">(b)</span></span> for any fiscal year of the person, derives at least 10% of revenues, determined on a consolidated basis in accordance with generally accepted accounting principles in Canada, from the manufacture or promotion of opioid products by that person or by other persons,</p><p class="para"><a name="d1e247"></a><span class="num"><span class="holder">(c)</span></span> engages in or causes, directly or indirectly, other persons to engage in promoting an opioid product, or</p><p class="para"><a name="d1e256"></a><span class="num"><span class="holder">(d)</span></span> is a trade association primarily engaged in</p><p class="subpara"><a name="d1e264"></a><span class="num"><span class="holder">(i) </span></span> advancing the interests of manufacturers,</p><p class="subpara"><a name="d1e273"></a><span class="num"><span class="holder">(ii) </span></span> promoting an opioid product, or</p><p class="subpara"><a name="d1e282"></a><span class="num"><span class="holder">(iii) </span></span> causing, directly or indirectly, other persons to engage in promoting an opioid product;</p><p id="d1e293" class="def"><span id="opioid+product" class="normal-bold-style">"opioid product"</span> means any product that contains</p><p class="para"><a name="d1e300"></a><span class="num"><span class="holder">(a)</span></span> a drug set out in the Schedule, or</p><p class="para"><a name="d1e309"></a><span class="num"><span class="holder">(b)</span></span> a drug prescribed by regulation;</p><p id="d1e373" class="def"><span id="opioid-related+wrong" class="normal-bold-style">"opioid-related wrong"</span> means</p><p class="para"><a name="d1e380"></a><span class="num"><span class="holder">(a)</span></span> a tort that is committed in British Columbia by a manufacturer or wholesaler and that causes or contributes to opioid-related disease, injury or illness, or</p><p class="para"><a name="d1e389"></a><span class="num"><span class="holder">(b)</span></span> in an action under section 2 (1), a breach, by a manufacturer or wholesaler, of a common law, equitable or statutory duty or obligation owed to persons in British Columbia who have used or been exposed to or might use or be exposed to an opioid product;</p></div><div class="pit"><p class="reference"><a name="pit3"> 
			</a>Section 1 (6) BEFORE amended by 2022-34-1(g), effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e698"></a><span class="num"><span class="holder">(6) </span></span>For the purposes of determining the market share of a defendant for a type of opioid product sold in British Columbia, the court must calculate the defendant's market share for the type of opioid product by the following formula:</p><table align="center" cellSpacing="0" cellPadding="3" border="0" class="tablestyle1"><tbody><tr><td colname="c1" valign="center" rowspan="3">dms = </td><td colname="c2">dm</td><td colname="c3" valign="center" rowspan="3">× 100%</td></tr><tr><td colname="c2"><hr /></td></tr><tr><td colname="c2">MM</td></tr></tbody></table><table cellSpacing="0" cellPadding="3" border="0" class="tablestyle4"><tbody><tr><td rowspan="4" width="84"> </td><td colname="c2" valign="top" colspan="3">where</td></tr><tr><td colname="c2" valign="top">dms</td><td colname="c3" valign="top" align="center"> = </td><td colname="c4" valign="top">the defendant's market share for the type of opioid product from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;</td></tr><tr><td colname="c2" valign="top">dm</td><td colname="c3" valign="top" align="center"> = </td><td colname="c4" valign="top">the quantity of the type of opioid product manufactured or promoted by the defendant that is distributed or sold within British Columbia from the date of the earliest opioid-related wrong committed by that defendant to the date of trial;</td></tr><tr><td colname="c2" valign="top">MM</td><td colname="c3" valign="top" align="center"> = </td><td colname="c4" valign="top">the quantity of the type of opioid product manufactured or promoted by all manufacturers or wholesalers that is purchased or dispensed within British Columbia for the purpose of providing health care benefits from the date of the earliest opioid-related wrong committed by the defendant to the date of trial.</td></tr></tbody></table></div><div class="pit"><p class="reference"><a name="pit4"> 
			</a>Section 1 (7) was added by 2022-34-1(h), effective November 3, 2022 (Royal Assent).</p></div><div class="pit"><p class="reference"><a name="pit5"> 
			</a>Section 2 (1) BEFORE amended by 2022-34-2, effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e823"></a><span class="num"><span class="holder">(1) </span></span>The government has a direct and distinct action against a manufacturer or wholesaler to recover the cost of health care benefits caused or contributed to by an opioid-related wrong.</p></div><div class="pit"><p class="reference"><a name="pit6"> 
			</a>Section 2.1 was enacted by 2022-34-3, effective November 3, 2022 (Royal Assent).</p></div><div class="pit"><p class="reference"><a name="pit7"> 
			</a>Section 3 (1) (part) BEFORE amended by 2022-34-4 and 5, effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e972"></a><span class="num"><span class="holder">(1) </span></span>In an action under section 2 (1) for the recovery of the cost of health care benefits on an aggregate basis, subsection (2) of this section applies if the government proves, on a balance of probabilities, that, in respect of a type of opioid product,</p></div><div class="pit"><p class="reference"><a name="pit8"> 
			</a>Section 4 (1) BEFORE amended by 2022-34-4, effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e1081"></a><span class="num"><span class="holder">(1) </span></span>Two or more defendants in an action under section 2 (1) are jointly and severally liable for the cost of health care benefits if</p><p class="para"><a name="d1e1089"></a><span class="num"><span class="holder">(a)</span></span> those defendants jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1), and</p><p class="para"><a name="d1e1098"></a><span class="num"><span class="holder">(b)</span></span> as a consequence of the breach described in paragraph (a) of this subsection, at least one of those defendants is held liable in the action under section 2 (1) for the cost of those health care benefits.</p></div><div class="pit"><p class="reference"><a name="pit9"> 
			</a>Section 4 (2) (part) BEFORE amended by 2022-34-4 and 6, effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e1108"></a><span class="num"><span class="holder">(2) </span></span>For purposes of an action under section 2 (1), 2 or more manufacturers or wholesalers, whether or not they are defendants in the action, are deemed to have jointly breached a duty or obligation described in the definition of "opioid-related wrong" in section 1 (1) if</p></div><div class="pit"><p class="reference"><a name="pit10"> 
			</a>Section 4 (2) (a) and (b) (part) BEFORE amended by 2022-34-6, effective November 3, 2022 (Royal Assent).</p><p class="para"><a name="d1e1116"></a><span class="num"><span class="holder">(a)</span></span> one or more of those manufacturers or wholesalers are held to have breached the duty or obligation, and</p><p class="para"><a name="d1e1125"></a><span class="num"><span class="holder">(b)</span></span> at common law, in equity or under an enactment, those manufacturers or wholesalers would be held</p></div><div class="pit"><p class="reference"><a name="pit11"> 
			</a>Section 5 (c) was added by 2022-34-7, effective November 3, 2022 (Royal Assent).</p></div><div class="pit"><p class="reference"><a name="pit12"> 
			</a>Section 6 BEFORE amended by 2022-34-8, effective November 3, 2022 (Royal Assent).</p><div class="section"><a name="section6"></a><h4><a name="section6"></a>Limitation periods</h4><p id="d1e1198" class="sec "><span class="secnum"><span class="secnumholder"><b>6</b>
		  <a name="d1e1206"></a>(1) </span></span>No action that is commenced by the government within 2 years after the coming into force of this section for the recovery of the cost of health care benefits, or for damages, alleged to have been caused or contributed to by an opioid-related wrong, is barred under the <em>Limitation Act</em>.</p><p class="sub"><a name="d1e1215"></a><span class="num"><span class="holder">(2) </span></span>Any action described in subsection (1) of this section for damages alleged to have been caused or contributed to by an opioid-related wrong is revived if the action was dismissed before the coming into force of this section merely because it was held by a court to be barred or extinguished by the <em>Limitation Act</em>.</p></div></div><div class="pit"><p class="reference"><a name="pit13"> 
			</a>Section 7 (2) (part) BEFORE amended by 2022-34-9, effective November 3, 2022 (Royal Assent).</p><p class="sub"><a name="d1e1246"></a><span class="num"><span class="holder">(2) </span></span>If the government is unable to establish which defendant caused or contributed to the use or exposure described in paragraph (b) and, as a result of a breach of a common law, equitable or statutory duty or obligation,</p></div><div class="pit"><p class="reference"><a name="pit14"> 
			</a>Section 7 (3) (e) BEFORE amended by 2022-34-6, effective November 3, 2022 (Royal Assent).</p><p class="para"><a name="d1e1321"></a><span class="num"><span class="holder">(e)</span></span> the degree to which a defendant collaborated or acted in concert with other manufacturers or wholesalers in any conduct that caused, contributed to or aggravated the risk of disease, injury or illness;</p></div><div class="pit"><p class="reference"><a name="pit15"> 
			</a>Section 7.1 was enacted by 2022-34-10, effective November 3, 2022 (Royal Assent).</p></div><div class="pit"><p class="reference"><a name="pit16"> 
			</a>Section 10 BEFORE amended by 2022-34-4, effective November 3, 2022 (Royal Assent).</p><div class="section"><a name="section10"></a><h4><a name="section10"></a>Retroactive effect</h4><p id="d1e1473" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>10</b>
		  </span></span>A provision of this Act has the retroactive effect necessary to give the provision full effect for all purposes, including allowing an action to be brought under section 2 (1) arising from an opioid-related wrong, whenever the opioid-related wrong occurred.</p></div></div><div class="pitlast"><p class="reference"><a name="pit17"> 
			</a>Schedule, section 1 (part) and table heading BEFORE amended by 2022-34-11, effective November 3, 2022 (Royal Assent).</p><div class="section"><a name="section1"></a><p id="d1e1798" class="sec nosubsecnum"><span class="secnum"><span class="secnumholder"><b>1</b>
		  </span></span>A product that contains any of the following drugs is an opioid product for the purposes of this Act:</p><table align="center" cellSpacing="0" cellPadding="3" border="1" class="tablestyle2"><tbody><tr><td colname="c1" valign="top" align="center" width="300"><strong>Drugs containing any of the following active ingredients</strong></td><td colname="c1" valign="top" align="center" width="300"><strong>Including but not limited to</strong></td></tr></tbody></table></div></div></div><p class="copyright">Copyright © King's Printer, Victoria, British Columbia,
					Canada</p></div></body></html>
